Business · NVIDIA Blog
The startup concept was sparked when Fred Parietti was at MIT doing PhD research in robotics and he met
Compiled by KHAO Editorial — aggregated from 1 outlet. See llms.txt for citation guidance.
★ Tier-1 Source
“She showed me what she did in a lab and how difficult it was, and I couldn’t believe it — I thought drugs were made like chips, and this was insane but also real,” said Parietti, cofounder and CEO of Multiply Labs.
Key facts
- Through advanced robotics, that cost can be reduced by more than 70%, bringing it down to $25,000 to $35,000 per dose
- San Francisco-based Multiply Labs, founded in 2016, today is automating cell therapy manufacturing with robots for leading companies, including Kyverna Therapeutics and Legend Biotech
- Today, manufacturing a single dose of cell therapy can cost upwards of $100,000
- We want to enable the shift of the industry from niche to scale — 100 times more therapies at 70% less cost — so life-saving treatments aren’t for the few, but for the millions,” said Parietti
Summary
Multiply Labs is doing for cell therapy labs what has already happened in the chip industry: It’s introducing robots to do the tedious, precision and hygienic work better, faster and cheaper. The startup concept was sparked when Fred Parietti was at MIT doing PhD research in robotics and he met with Alice Melocchi, who showed him how these laborious labs lacked automation while risking contamination. San Francisco-based Multiply Labs, founded in 2016, today is automating cell therapy manufacturing with robots for leading companies, including Kyverna Therapeutics and Legend Biotech. Multiply Labs offers end-to-end robotic systems that produce gene modified cell therapies at scale.